Topic List : Neuroscience
Brainlike computers come of age
Conventional computer chips aren’t up to the challenges posed by next-generation autonomous drones and medical implants. Now, Kwabena Boahen has laid out a way forward, using ideas built in to our brains.
Training improves memory, changes brain
Stanford scientists found that teaching ordinary people a technique used by “memory athletes” not only boosted their recall ability but also induced lasting changes in the organization of their brains.
Fast, brain-controlled typing achieved
In a Stanford-led research report, three participants with movement impairment controlled an onscreen cursor simply by imagining their own hand movements.
Listening to the brain
Stanford engineers and neurosurgeons have worked together to develop an experimental technology that could one day allow people with paralysis to affect the world around them using only their minds.
Circuitry of Parkinson’s revealed
The new Stanford technique probes the neural pathways that cause these tremors, and also provides a way to map and troubleshoot other circuits in the brain.
Deisseroth wins Harvey Prize
Karl Deisseroth is one of two recipients of the 2016 Harvey Prize in Human Health, which is being awarded for the development of optogenetics.
Toxic brain cells may drive neurologic disease
Astrocytes, star-shaped cells in the central nervous system, are essential to the survival and healthy function of brain neurons. But aberrant astrocytes may be driving neurodegenerative disorders.
Seizure ‘choke point’ in brain
Stanford researchers used a rodent model to discover that shifting the firing pattern of a particular set of brain cells is all it takes to initiate, or to terminate, an absence seizure.
Measuring electrical stimulation of brain tissue
Until now, no quantitative relationship between the level of electricity applied to the brain and the extent of neural activity generated has been plotted in humans.
Child’s life saved by experimental drug
Four-year-old Zoe Harting is doing well after participating in a phase-2 clinical trial of the first drug for a deadly genetic disease, spinal muscular atrophy type 1.